Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes

Mazhar Hussain 1, Asim Elahi 2, Javed Iqbal 3, Muhammad Bilal Ghafoor 4, Habib Rehman 3, Shoaib Akhtar 3

1. Pharmacology, Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, PAK
2. Internal Medicine, Pikeville Medical Center, Pikeville, USA
3. Medicine, Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, PAK
4. Pathology, Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, PAK

Corresponding author: Mazhar Hussain, mazharhussain214@gmail.com

Abstract

Background

Type 2 diabetes is a chronic metabolic disorder that is escalating at an alarming rate worldwide. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are recent oral antihyperglycemic drugs (OADs) with a unique mechanism of action.

Objectives

This study aimed to compare the efficacy and safety profiles of two SGLT-2 inhibitors, empagliflozin and dapagliflozin, in patients with type 2 diabetes as add-on therapy to traditional first-line OADs.

Methods

We conducted a randomized controlled trial comparing empagliflozin and dapagliflozin in patients with type 2 diabetes. Patients were included in the study if they had type 2 diabetes with inadequate glycemic control, defined as glycated hemoglobin (HbA1c) of 7.5% to 11.0%, treated with conventional first-line OADs. Study participants were randomly assigned into two groups. Group A patients received oral empagliflozin, 10 to 25 mg, and Group B patients received oral dapagliflozin, 5 to 10 mg, for 12 weeks. The primary endpoint was the efficacy profile for each SGLT-2 agent in terms of body weight changes, body mass index (BMI), fasting blood glucose (FBG), and HbA1c. The secondary endpoint was to determine the safety and tolerability profiles of each SGLT-2 agent.

Results

After 12 weeks of treatment, the mean body weight was reduced significantly in both groups from baseline (empagliflozin: -3.2 kg ± 5.5 kg, p = 0.003; dapagliflozin: -2.1 kg ± 4.6 kg, p = 0.008). However, the mean body weight reduction between groups was not statistically significant (p = 0.078). BMI was significantly reduced in both groups (empagliflozin from 28.5 ± 4.9 kg/m² to 25.8 ± 5.2 kg/m², p = 0.002; dapagliflozin from 29 ± 5.2 kg/m² to 27.7 ± 4.8 kg/m², p = 0.003). However, the patients who received empagliflozin experienced a significantly greater reduction in BMI than patients who received dapagliflozin (p = 0.007). The mean FBG was also reduced in both study groups (empagliflozin: -88.5 mg/dL ± 39.7 mg/dL, p = 0.003; dapagliflozin: -59.8 mg/dL ± 48.5 mg/dL, p = 0.007). However, the patients who received empagliflozin experienced a significantly greater reduction in mean FBG than patients who received dapagliflozin (p = 0.001). HbA1c was also significantly reduced in both groups (empagliflozin: -2.1% ± 1.1%, p = 0.002; dapagliflozin: -1.4% ± 0.9%, p = 0.004). However, patients who received empagliflozin experienced a significantly greater reduction in HbA1c than patients who received dapagliflozin (p = 0.001).

The tolerability profiles of both SGLT-2 agents were quite good, and no major adverse effects were reported in the study groups. Urinary infection occurred more often in patients who received dapagliflozin (9.3%) than in patients who received empagliflozin (4.5%; p = 0.002). Patients in the dapagliflozin group also had a higher incidence of genital infections (7.3%) than those in the empagliflozin group (3.8%; p = 0.001).

Conclusion

Both empagliflozin and dapagliflozin demonstrated excellent efficacy and safety profiles in our study. These agents should be considered as add-on therapy in patients with type 2 diabetes taking conventional first-line OADs.
Materials And Methods

We conducted a 12-week randomized, controlled trial at five private clinics and the diabetes clinic of Sheikh Zayed Hospital. A total of 615 patients were recruited from these clinical settings, and 542 patients met the inclusion criteria and were enrolled in the study. To be included in the study, patients had to have type 2 diabetes with inadequate glycemic control defined as glycated hemoglobin (HbA1c) of 7.5% to 11% treated with different first-line OAD combinations, such as metformin, pioglitazone, glibenclamide, glimepiride, sitagliptin, and vildagliptin. The study excluded patients with a history of type 1 diabetes, ketoacidosis, significant hepatic disease, cardiovascular disease, unstable/rapidly progressing renal disease, malignancy, pancreatic disorders, genitourinary infection, and steroid use. All study participants provided informed written consent for inclusion in the study. The study protocol was approved by the Institutional Review Board of Sheikh Zayed Medical College and Hospital.

The study population was divided into two groups via random sampling. Group A patients were given once-daily oral empagliflozin, 10 mg to 25 mg, and patients in Group B were given once-daily dapagliflozin, 5 mg to 10 mg, as an add-on therapy for 12 weeks. The doses of SGLT-2 inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, and metformin were maintained during the study, while sulphonylurea doses were reduced if patients developed hypoglycemic episodes.

The study’s primary endpoint assessed each drug’s efficacy by measuring body weight changes, body mass index (BMI), fasting blood glucose (FBG), and HbA1c from baseline. The secondary endpoint was determining each drug’s safety and tolerability profiles by assessing adverse effects from baseline. All the parameters were measured before starting SGLT-2 inhibitor therapy and at the end of the study. FBG was analyzed via the glucose oxidase peroxidase method. HbA1c was measured by liquid chromatography, while fasting serum lipid profile was measured by the enzymatic endpoint method.
Data analysis
Data were analyzed using the Statistical Package for Social Sciences (SPSS) for Windows, version 16.0 (SPSS, Inc., Chicago, IL). The values of numeric data were expressed as mean ± standard deviation (SD). The frequency data were expressed as a percentage. The difference in the primary endpoint from baseline was analyzed using the paired t-test, while the difference in secondary endpoints from baseline was determined via the Chi-square test. We considered p < 0.05 as statistically significant and p < 0.01 as highly significant.

Results
A total of 615 patients with type 2 diabetes were recruited, of whom 420 were considered for the study. Seventy-eight patients were excluded, leaving a total of 342 patients included in the study, randomized into two groups. Sixteen patients in the empagliflozin group and 21 patients in the dapagliflozin group were dropped out. One hundred fifty-five patients received empagliflozin, and 150 patients received dapagliflozin (Figure 1).

FIGURE 1: Study Flow Chart
There was no difference in the baseline demographic characteristics and clinical study parameters in both study groups at the start of the study. The number of patients taking other OADs is presented in Table 1.
| Patient Characteristics | Empagliflozin (n = 155) | Dapagliflozin (n = 150) | P-value |
|-------------------------|-------------------------|-------------------------|---------|
| Age (years)             | 52.5 ± 15.6             | 49.4 ± 18.2             | 0.63    |
| Gender (M/F)            | 109 (70%)/46 (30%)      | 100 (67%)/50 (33%)      | 0.32    |
| Body weight (kg)        | 93.5 ± 18.4             | 95.6 ± 21               | 0.42    |
| BMI (kg/m²)             | 28.5 ± 4.9              | 29 ± 5.2                | 0.96    |
| Diabetes duration (years)| 9.2 ± 3.8               | 8.9 ± 5.6               | 0.72    |
| Clinical Parameters (mean ± SD) |                      |                         |         |
| FBG (mg/dL)             | 188 ± 36.5              | 195 ± 42                | 0.81    |
| HbA1c (%)               | 10.1 ± 3.4              | 9.5 ± 2.8               | 0.36    |
| Total Cholesterol (mg/dL)| 164 ± 32.5             | 142 ± 26.5              | 0.52    |
| Triglycerides (mg/dL)   | 187 ± 29.7              | 190 ± 35.6              | 0.71    |
| LDL Cholesterol (mg/dL) | 98 ± 32                 | 108 ± 18.5              | 0.42    |
| HDL Cholesterol (mg/dL) | 40.5 ± 6.6              | 43 ± 7.8                | 0.64    |
| Concomitant OAD (N (%)) |                        |                         |         |
| Biguanides              | 21 (13.5%)              | 22 (14.6%)              | 0.42    |
| Thiazolidinediones      | 3 (2%)                  | 5 (3.3%)                | 0.71    |
| DPP-4 Inhibitors        | 10 (6.4%)               | 12 (8%)                 | 0.32    |
| Sulphonylurea           | 16 (10.3%)              | 11 (7.3%)               | 0.66    |
| Sulphonylurea + Biguanides| 38 (24.5%)             | 42 (28%)                | 0.28    |
| Sulphonylurea + Thiazolidinediones | 10(6.4%)      | 9 (6%)                  | 0.39    |
| DPP-4 Inhibitors + Biguanides | 40 (25.8%)            | 35 (23.3%)              | 0.64    |
| Thiazolidinediones + Biguanides | 17 (11%)              | 14 (8.3%)               | 0.34    |

**TABLE 1: Baseline Characteristics, Clinical Parameters, and Concomitant Therapies**

BMI: body mass index; DPP-4: dipeptidyl peptidase-4; FBG: fasting blood glucose; HbA1c: glycated hemoglobin; HDL: high-density lipoprotein; LDL: low-density lipoprotein; OAD: oral antihyperglycemic drug; SD: standard deviation

After 12 weeks of treatment, the mean body weight was reduced significantly in both groups. Patients receiving empagliflozin had a mean body weight reduction from baseline of 3.2 kg ± 5.5 kg (p = 0.003), and patients receiving dapagliflozin had a mean body weight reduction of 2.1 kg ± 4.6 kg (p = 0.008). The difference in mean body weight between patients receiving empagliflozin and patients receiving dapagliflozin at the end of the study was not statistically significant (p = 0.078). BMI was significantly reduced in both groups (empagliflozin from 28.5 ± 4.9 kg/m² to 25.8 ± 5.2 kg/m², p = 0.002; dapagliflozin from 29 ± 5.2 kg/m² to 27.7 ± 4.8 kg/m², p = 0.003). However, the patients who received empagliflozin experienced a significantly greater reduction in BMI than patients who received dapagliflozin (p = 0.007).

Similarly, the mean FBG was significantly reduced in both study groups. Patients receiving empagliflozin had a mean FBG reduction of 88.5 mg/dL ± 39.7 mg/dL (p = 0.005). Patients receiving dapagliflozin had a mean FBG reduction of 59.8 mg/dL ± 48.5 mg/dL (p = 0.007). However, patients who received empagliflozin experienced a significantly greater reduction in mean FBG than patients who received dapagliflozin (p = 0.001) after 12 weeks of treatment.

The mean HbA1c was also significantly reduced in both groups. Patients who received empagliflozin had a mean HbA1c reduction by 2.1% ± 1.1% (p = 0.002), and patients who received dapagliflozin had a mean HbA1c reduction by 1.4% ± 0.9% (p = 0.004). Patients who received empagliflozin experienced a significantly greater reduction in the mean HbA1c than patients who received dapagliflozin (p = 0.001) after 12 weeks of treatment (Table 2).
### TABLE 2: Changes From Baseline in Both Study Groups

† Differences within groups measured at baseline and week 12
‡ Differences within the group measured at baseline and week 12

BMI: body mass index; FBG: fasting blood glucose; HbA1c: glycated hemoglobin

Both drugs’ tolerability profiles were quite good, and no major adverse effects were reported in either study group. However, minor adverse effects were observed in both study groups (Table 4).

### TABLE 3: Adverse Effects

Urinary infections occurred more often in patients who received dapagliflozin (9.3%) than in patients who received empagliflozin (4.5%; p = 0.002). Patients in the dapagliflozin group also had a higher incidence of genital infections (7.3%) than those in the empagliflozin group (3.8%; p = 0.001).

### Discussion

The present study was conducted to determine the efficacy and safety profiles of empagliflozin compared with dapagliflozin as an add-on therapy in patients with type 2 diabetes experiencing inadequate glycemic control with conventional first-line OADs. Both empagliflozin and dapagliflozin have excellent efficacy and safety profiles. However, empagliflozin caused a more significant improvement in mean body weight, FBG, and HbA1c with fewer adverse effects than dapagliflozin.

The pharmacologic management of diabetes changes over time due to its progressive nature. This makes achieving optimal glycemic control with monotherapy a challenge and eventually causes patients to need two to four OADs as combination therapy, as recommended by both the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [11].

In our study, both empagliflozin and dapagliflozin significantly reduced body weight and HbA1c. These results support the findings reported in another study conducted in two different cohorts at 12 and 24 weeks.
where empagliflozin produced similar reductions in body weight and HbA1c [12]. Similarly, another clinical study reported that dapagliflozin reduced HbA1c and body weight over 152 weeks in patients with inadequate glycemic control via metformin [13]. Both studies compared the SGLT-2 inhibitor against a placebo control group, while our study compared the outcomes of two SGLT-inhibitors against each other.

Our results were similar to those of a 52-week study by Ku et al., who reported that empagliflozin reduced body weight, blood glucose levels, and HbA1c to a greater degree than dapagliflozin [14]. Ku et al. also reported that empagliflozin improved cardiometabolic risk factors more significantly than dapagliflozin and had a low incidence of genitourinary infection.

A review regarding the efficacy, safety, and tolerability of different SGLT-2 inhibitors demonstrated that empagliflozin is one of the safer choices and can be prescribed in patients with type 2 diabetes with renal impairment (a parameter that our study did not explore) [15].

A study conducted in the United Arab Emirates reported that canagliflozin (300 mg), in combination with metformin for 26 weeks, provided a greater reduction in HbA1c (-0.79%) than empagliflozin 25 mg (-0.64%) and dapagliflozin 10 mg (-0.41%) [16]. A study conducted in China reported that empagliflozin and dapagliflozin reduced body weight, FBG, and HbA1c for patients with type 2 diabetes, similar to our results [17]. Also, both drugs ameliorated hepatic dysfunction and improved insulin resistance over six months [17].

The efficacy, safety, and tolerability profile of empagliflozin and dapagliflozin as an add-on therapy were investigated in various clinical studies that yielded similar results to our study [18-26]. Both drugs reduced body weight and provided excellent glycemic control with no risk of severe hypoglycemia. Moreover, the risk of urogenital infection varied from 1% to 9%, which is similar to the risk we found.

The risk of atherosclerotic disease is very high in patients with type 2 diabetes. Treatment with dapagliflozin provides cardiovascular safety with a low rate of cardiovascular death and hospitalization due to heart failure [27]. Empagliflozin also reduces cardiovascular events and delays kidney disease progression in patients with type 2 diabetes with cardiovascular comorbidities. A systematic review and meta-analysis of 27 studies also showed that SGLT-2 inhibitors reduced the risk of renal and cardiovascular disease impairment in patients with chronic kidney disease and patients with diabetes [28].

Conclusions

Both empagliflozin and dapagliflozin have excellent efficacy, safety, and tolerability profiles. They can be safely used as an add-on therapy to conventional OADs in patients with type 2 diabetes. There is a further need to explore the efficacy and safety of SGLT-2 inhibitors in diabetic patients with cardiovascular disease and renal impairment. Moreover, a study with a larger sample size and longer duration is warranted to confirm the safety and tolerability profile.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Review Board, Sheikh Zayed Medical College and Hospital issued approval 26/IRB/SZMC/SZH. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We appreciate the cooperation of Dr. Muhammad Bilal Ghafoor and his laboratory staff.

References

1. Zheng Y, Ley SH, Hu FB: Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018, 14:88-98. 10.1038/nrendo.2017.151
2. Saeedi P, Petersohn I, Salpea P, et al.: Global and regional diabetes prevalence estimates for 2019 and projections with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We appreciate the cooperation of Dr. Muhammad Bilal Ghafoor and his laboratory staff.

References

1. Zheng Y, Ley SH, Hu FB: Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018, 14:88-98. 10.1038/nrendo.2017.151
2. Saeedi P, Petersohn I, Salpea P, et al.: Global and regional diabetes prevalence estimates for 2019 and projections with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We appreciate the cooperation of Dr. Muhammad Bilal Ghafoor and his laboratory staff.

References

1. Zheng Y, Ley SH, Hu FB: Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018, 14:88-98. 10.1038/nrendo.2017.151
2. Saeedi P, Petersohn I, Salpea P, et al.: Global and regional diabetes prevalence estimates for 2019 and projections with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We appreciate the cooperation of Dr. Muhammad Bilal Ghafoor and his laboratory staff.
5. Qaseem A, Barry MJ, Humphrey LL, Forciea MA: Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017, 166:279-290. 10.7326/M16-1860
6. Donnall JR, Grandy CA, Chirikov E, et al.: Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. 2019, 9:e022577. 10.1136/bmjopen-2018-022577
7. Kalra S: Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther. 2014, 5:355-366. 10.1007/s13300-014-0089-4
8. Satoh H: Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control. Diabetol Int. 2018, 9:212-214. 10.1007/s13590-018-0567-x
9. Gardafalo C, Borrelli S, Liberti ME, et al.: SGLT2 inhibitors: nephroprotective efficacy and side effects. Medicina (Kaunas). 2019, 55:268. 10.3390/medicina55060268
10. American Diabetes Association: 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019, 42:S90-S102. 10.2337/dc19-0009
11. Inzucchi SE, Bergenstal RM, Buse JB, et al.: Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012, 55:1577-1596. 10.1007/s00125-012-2534-0
12. Neeland JJ, McGuire DK, Chilton R, et al.: Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016, 15:119-126. 10.1177/1479164115616901
13. Bolinder J, Ljunggren Ö, Johansson L, et al.: Dapagliflozin maintains glycemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014, 16:159-169. 10.1111/dom.12189
14. Ku EL, Lee DH, Jeon HJ, Oh TK: Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: a 52-week prospective observational study. Diabetes Res Clin Pract. 2019, 151:S5-7. 10.1016/j.diabres.2019.04.008
15. Syed SH, Gosavi S, Shami W, et al.: A review of sodium glucose co-transporter 2 inhibitors canagliflozin, dapagliflozin and empagliflozin. Cardiovasc Hematol Agents Med Chem. 2015, 13:105-112. 10.2174/1573399813666170816142351
16. Schubert A, Buchholtz AT, El Khoury AC, et al.: Evaluating the costs of glyemic response with empagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. Curr Med Res Opin. 2017, 33:1155-1163. 10.1080/03007995.2017.1310091
17. Lee PCH, Gu Y, Yeung MY, et al.: Dapagliflozin and empagliflozin ameliorate hepatic dysfunction among Chinese subjects with diabetes in part through glycemic improvement: a single-center, retrospective, observational study. Diabetes Ther. 2018, 9:285-295. 10.1007/s13300-017-0355-5
18. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ: Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycemia. Diabetes Obes Metab. 2015, 17:1154-1160. 10.1111/dob.12185
19. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC: Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014, 16:147-158. 10.1111/dob.12188
20. Hadjadj S, Rosenstock J, Meinicke T, Woerle HJ, Broedl UC: Initial combination of empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care. 2016, 39:1718-1728. 10.2337/dc16-0522
21. Romera I, Gomis R, Crowe S, et al.: Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials. J Diabetes Complications. 2016, 30:1571-1576. 10.1016/j.diabcomp.2016.07.016
22. Fioretto P, Giacchi A, Sesti G: Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015, 14:142. 10.1186/s12933-015-0297-x
23. Jabbour SA, Hardy E, Sugg J, Parikh S; Study 10 Group: Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014, 37:740-750. 10.2337/dc13-0467
24. Matthari S, Bowering K, Rohwedder K, Grohl A, Parikh S; Study 05 Group: Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015, 38:365-372. 10.2337/dc14-0666
25. Müller-Wieland D, Kellerer M, Cypryk K, et al.: Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2018, 20:2598-2607. 10.1111/dob.13437
26. Frías JP, González-Galvez G, Jonsson EK, Maaske J, Peters A: 261-OR: Dapagliflozin plus saxagliptin add-on vs. glimepiride add-on to metformin in patients with poorly controlled type 2 diabetes. Diabetologia. 2018, 61:567-570. 10.2337/db17-261-OR
27. Wiviott SD, Raz I, Bonaca MP, et al.: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:547-557. 10.1056/NEJMoa1812389
28. Minne MG, Will KJ, Terrell BT, Black RL, Irons BK: Benefits of SGLT2 inhibitors beyond glycemic control-a focus on metabolic, cardiovascular and renal outcomes. Curr Diabetes Rev. 2018, 14:509-517. 10.2174/1573399813666170816142351